Clinical trial
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With…
NCT00103571 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00103571 |
|---|---|
| Title | Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia |
| Official title | Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Olanzapine, Aripiprazole |
| Enrollment | 600 |
| Start date | Jul 1, 2004 |
| Completion | Aug 1, 2006 |
| First posted | Feb 11, 2005 |
| Last update posted | Nov 6, 2007 |
| Countries | Puerto Rico, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: